ANIP — ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $247.1 million, up 30% year-over-year.
• Full Year 2025 Revenue: $883.4 million, a 44% increase from 2024.
• Cortrophin Gel Revenue: $111.4 million in Q4, up 88% year-over-year; $347.8 million for the full year, up 76%.
• Generics Revenue: $100.8 million in Q4, a 28% increase; $384.1 million for the full year, also up 28%.
• Adjusted Non-GAAP EBITDA: $65.4 million in Q4, up 31%; $229.8 million for the full year, up 47%.
• Adjusted Non-GAAP EPS: $2.33 in Q4 vs. $1.63 in the prior year; $7.89 for the full year vs. $5.20.
• Cash Position: $285.6 million in unrestricted cash at year-end, up from $144.9 million in 2024.

2. Strategic Updates and Business Highlights

• ANI is focusing on becoming a leading rare disease company, with Cortrophin Gel as a key asset.
• Plans to expand the sales force by 90 personnel dedicated to acute gouty arthritis, targeting underpenetrated specialties.
• Continued investment in generics, maintaining a launch cadence of 10-15 products annually.
• The company is enhancing patient access initiatives for Cortrophin and ILUVIEN, including a prefilled syringe offering for Cortrophin.
• Ongoing clinical trials and evidence generation to support Cortrophin's market position.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: $1.055 billion to $1.115 billion, representing a year-over-year growth of 19% to 26%.
• Cortrophin Gel Revenue Guidance: $540 million to $575 million, with expected growth of 55% to 65%.
• Adjusted Non-GAAP EBITDA Guidance: $275 million to $290 million, reflecting a growth of 20% to 26%.
• Anticipated challenges in Q1 due to typical seasonality and insurance reverification delays, with expected recovery in Q2 and beyond.

4. Bad News, Challenges, or Points of Concern

• Market Access Issues: No significant changes in patient access or payer coverage for Cortrophin were reported.
• Gross Margin Pressure: Non-GAAP gross margin decreased to 59.6% in Q4, attributed to product mix and increased sales of royalty-bearing products.
• Royalty Rate Increase: The royalty rate for Cortrophin is expected to step up to the high 20s in 2026, impacting margins.
• Dependence on Gout Expansion: The success of the new sales force dedicated to gout is critical for future growth, and any delays could impact revenue expectations.

5. Notable Q&A Insights

• Management emphasized the multiyear growth potential for Cortrophin, citing significant underpenetrated patient populations and the unique position of Cortrophin as the only approved ACTH therapy for acute gouty arthritis.
• The sales force expansion is primarily focused on gout but can also address other indications, leveraging existing relationships with prescribers.
• Questions regarding the competitive landscape indicated that the focus is on market expansion rather than share capture among existing ACTH products.
• Concerns about the sustainability of patient access and the impact of external factors like insurance coverage were acknowledged, with management expressing confidence in their strategic initiatives to navigate these challenges.

Overall, ANI Pharmaceuticals reported strong financial results for 2025, with significant growth in both its rare disease and generics segments. The company is strategically positioned for continued growth in 2026, although it faces challenges related to market access and gross margins that could impact performance.